INS and Hypoglycemia: Institution of inhaled insulin therapy, by improving metabolic control and ameliorating glucotoxicity, and possibly lipotoxicity, can lead to enhanced insulin sensitivity and beta cell function and may serve as an alternative insulin agent in patients reluctant to administer multiple subcutaneous injections of insulin daily or in patients who experience late postprandial hypoglycemia with subcutaneous insulin.